AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
VaxGen, Genentech amend agreement regarding AIDS vaccine candidate.(Brief Article)
2002 AUG 14 - (NewsRx.com & NewsRx.net) -- VaxGen, Inc., (VXGN) announced that its May 1, 1997, license and supply agreement with Genentech, Inc., (DNA) has been revised to give VaxGen greater flexibility in commercializing the company's AIDS vaccine candidate.
While Genentech maintains its option to market and sell the vaccine candidate in North America, the company has relinquished its option to commercialize it in the rest of the world.
The new agreement also reduces VaxGen's royalty obligations to Genentech for sales to the World Health Organization or United Nations for underdeveloped countries by up to 50% so that the vaccine can be made more widely available there. "This reflects the commitments of VaxGen and Genentech to ensure that AIDSVAX reaches not only the affluent markets but also countries where the AIDS epidemic is at its worst," said Donald P. Francis, MD, DSc, VaxGen's president.
Additionally, the agreement formalized Genentech's previous decision to waive its option to manufacture the vaccine candidate. "VaxGen and Genentech agreed that, given VaxGen's role in advancing the project, VaxGen should have control over the manufacturing of the AIDSVAX vaccine," said Lance K. Gordon, PhD, VaxGen's chief executive officer.
The revisions ...
- FDA Clears VaxGen's IND for Anthrax Vaccine Candidate; Clinical Development to...
- Press release article from: PR Newswire May 27, 2003 700+ words
...million doses. VaxGen intends to produce the vaccine candidate at its manufacturing...contract. VaxGen's anthrax vaccine candidate is based on...toxins. The vaccine candidate cannot cause...infection. About VaxGen VaxGen, Inc...
- VaxGen Receives Fast Track Designation for Its Anthrax Vaccine Candidate.
- Press release article from: PR Newswire January 21, 2004 700+ words
...for our anthrax vaccine candidate," said Carmen Betancourt, VaxGen's senior vice...products, including VaxGen's product candidates...research on its HIV vaccine candidate. For more information...http://www.vaxgen.com/. NOTE...
- VaxGen Reports Positive Results of Animal Efficacy Studies of Smallpox Vaccine...
- Press release article from: PR Newswire April 14, 2004 700+ words
VaxGen, Inc. today announced...its attenuated smallpox vaccine candidate, LC16m8. Both studies...K. Gordon, Ph.D., VaxGen's president and chief...The studies were funded by VaxGen and the National Institute...
- VaxGen Publishes Results of Phase I Clinical Trial of Anthrax Vaccine Candidate.
- Press release article from: PR Newswire August 14, 2006 700+ words
...study was funded by VaxGen's contract N01...About rPA102 VaxGen's rPA102 vaccine candidate is a recombinant...USAMRIID). The vaccine candidate contains the protein...infection. About VaxGen VaxGen, Inc. is...
- VaxGen Awarded $80.3 Million NIAID Contract for Advanced Development of Anthrax...
- Press release article from: PR Newswire October 1, 2003 700+ words
...latest contract. VaxGen's anthrax vaccine candidate is based on the pioneering...animal models. The vaccine candidate is composed of an...anthrax toxins. The vaccine candidate cannot cause anthrax infection. VaxGen began developing...
- Published Study Demonstrates Single Dose of VaxGen's Smallpox Vaccine Candidate...
- Press release article from: PR Newswire September 2, 2005 700+ words
...PRNewswire-FirstCall/ -- VaxGen, Inc. (VXGN.PK) announced...showing that a single dose of VaxGen's smallpox vaccine candidate LC16m8 provides mice with 100...Institute in Japan. About LC16m8 VaxGen is developing LC16m8 in the...
- VaxGen Phase I/II Study of Attenuated Smallpox Vaccine Candidate Completes...
- Press release article from: PR Newswire July 11, 2005 700+ words
...PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets: VXGN...to its attenuated smallpox vaccine candidate, LC16m8. LC16m8 has been...clinical study. About LC16m8 VaxGen is developing LC16m8 in the...2) and mice(3). About VaxGen, Inc. VaxGen, Inc. is...
- VaxGen to Present Interim Results of Phase I/II Clinical Trial of Smallpox...
- Press release article from: PR Newswire March 8, 2005 700+ words
VaxGen, Inc. (Pink Sheets: VXGN.PK...of LC16m8, will present data on VaxGen's smallpox vaccine candidate at the 2005 ASM Biodefense Conference...www.asmbiodefense.org/ or from VaxGen upon request. About VaxGen VaxGen...